American Healthcare REIT vs CoreCivic
AHR and CXW side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHR and CXW compare
American Healthcare REIT is the larger company, worth 4.1 times as much as CoreCivic ($12.7B against $3.1B).
On earnings, CoreCivic is cheaper: it trades at 24.8× trailing earnings, against 85.4× for American Healthcare REIT.
CoreCivic grew revenue faster over the last twelve months (24.3% versus 16.4% for American Healthcare REIT).
American Healthcare REIT pays a dividend yielding 1.7%; CoreCivic does not pay one.
American Healthcare REIT scores higher on the StockData Score (11 against 4 for CoreCivic), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHR | CXW |
|---|---|---|
| Size and price | ||
| Market cap | $12.7B | $3.1B |
| Share price | $58.07 | $30.97 |
| Change, 1 year | 20.4% | 84.9% |
| Change, 5 years | – | 174% |
| Beta (5Y) | 0.07 | 0.33 |
| Employees | 121 | 14K |
| StockData Score | ||
| Total score | 11 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 2 | 2 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | 85.4× | 24.8× (better) |
| P/S | 5.1× | 1.2× (better) |
| P/B | 3.4× | 2.1× (better) |
| EV/EBITDA | 17.3× | 11.2× (better) |
| P/FCF | – | 51.9× |
| PEG | – | 15.56 |
| FCF yield | – | 1.9% |
| Fair value | $22.96 | $24.62 |
| Margin of safety | −153% | −25.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.4% | 24.3% (better) |
| Revenue growth, 5Y average | 16.2% (better) | 3.0% |
| EPS growth (TTM) | – | 33.0% |
| EPS growth, 5Y average | 53.1% (better) | 19.1% |
| Profitability | ||
| Gross margin | 21.2% | – |
| Operating margin | 19.2% | – |
| Net margin | 4.8% | – |
| FCF margin | – | 2.4% |
| Return on equity | 4.0% | – |
| Return on invested capital | 16.5% | – |
| Financial health | ||
| Debt / equity | – | 0.94 |
| Net debt / EBITDA | – | 3.23 |
| Interest coverage | 6.2× | – |
| Current ratio | – | 1.32 |
| Altman Z-score | 4.19 (better) | 1.67 |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | – |
| Payout ratio | 148% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 3.1% | – |
| Buyback yield | −10.6% | 6.2% (better) |
| Shareholder yield | −8.9% | 6.2% (better) |
| Ownership | ||
| Held by institutions | 103% | 87.7% |
| Held by insiders | 0.63% | 2.2% |
| Insider net buying, 12 months | −$4.6M (better) | −$18.0M |
| Short interest, % of float | 15.5% | 13.1% |
Go deeper
- AHR stock overview
- AHR income statement
- AHR valuation and score
- CXW stock overview
- CXW income statement
- CXW valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.